Hemab raises USD 55m for treatment of rare bleeding disorders

In less than a year, Danish biotech company Hemab, which builds on technology developed by Novo Nordisk and Genmab, has gone from seed investments to a large capital fund raising round – and now to clinical trials.

Hemab's new CEO, Benny Sørensen | Photo: Hemab / PR

Things have moved quickly at Hemab since the company was founded almost two years ago – and gone even faster since the company secured an introductory seed investment from Novo Holdings in December.

Now, just over six months later, the company has received a series A investment of USD 55m (DKK 350m) from Novo Holdings and two other venture capital funds, Healthcap and RA Capital Management. The company is therefore now able to start clinical trials and put power behind its development of projects within rare bleeding disorders.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs